Characterization of a novel potency endpoint for the evaluation of immune checkpoint blockade in humanized miceFRONTIERS IN IMMUNOLOGYIF5.92023-03-030OAAI
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remainREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52023-02-018OAAI
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approachREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52023-02-0114OAAI
Opportunities for use of one species for longer-term toxicology testing during drug development: A cross-industry evaluationREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52020-06-0127OAAI
Monoclonal antibody targeting of fibroblast growth factor receptor 1c causes cardiac valvulopathy in ratsTOXICOLOGY AND APPLIED PHARMACOLOGYIF3.42018-09-012PREAI
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion ProteinMOLECULAR CANCER THERAPEUTICSIF5.52018-04-3036OAAI
The future trajectory of adverse outcome pathways: a commentary不良结果途径的未来轨迹: 评论ARCHIVES OF TOXICOLOGYIF6.92018-03-1624OAAI
MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potentialONCOIMMUNOLOGYIF6.32017-02-0336OAAI
Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new InsightsREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52016-10-0115PREAI
Nonclinical safety testing of biopharmaceuticals - Addressing current challenges of these novel and emerging therapiesREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52015-10-0113PREAI
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trialsREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52014-10-0122OAAI
New challenges and opportunities in nonclinical safety testing of biologicsREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52014-07-0119PREAI
Current challenges and opportunities in nonclinical safety testing of biologicsDRUG DISCOVERY TODAYIF7.52013-12-0119PREAI
Challenges and approaches for the development of safer immunomodulatory biologicsNATURE REVIEWS DRUG DISCOVERYIF101.82013-03-28169OAAI
Monoclonal antibody therapeutics: history and future单克隆抗体治疗: 历史与未来CURRENT OPINION IN PHARMACOLOGYIF4.22012-10-01398PREAI
The design of chronic toxicology studies of monoclonal antibodies: Implications for the reduction in use of non-human primatesREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52012-03-0139PREAI
Trafficking of exogenous peptides into proteasome-dependent major histocompatibility complex class I pathway following enterotoxin B subunit-mediated deliveryJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92004-12-0111OAAI
The role of ADP-ribosylation and GM1-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxinIMMUNOLOGY AND CELL BIOLOGYIF31998-05-0139PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向